Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).


ABULKHAIR O., USLU R. , SEZGIN C., BUEYUEKBERBER S., DARWISH T., ISIKDOGAN A., et al.

CANCER RESEARCH, cilt.72, 2012